The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Abstract
PURPOSE: The pharmacology and tolerability of exenatide in patients with type 2 diabetes mellitus were studied. METHODS: Two randomized, single-blind, placebo-controlled studies were conducted. Treatment with oral antidiabetic agents was stopped 14 days before study initiation. In the first study (study A), eight subjects received placebo, 0.1-, 0.2-, 0.3-, and either 0.4-microg/kg exenatide or placebo five minutes before a meal combined with liquid acetaminophen (to assess the rate of gastric emptying) on days 1, 3, 5, 7, and 9. In the second study (study B), subjects received a single s.c. dose of exenatide or placebo on consecutive days. Part 1 of study B used exenatide doses of 0.01 and 0.1 microg/ kg; 0.02-, 0.05-, and 0.1-microg/kg doses were given in part 2. After an overnight fast, the study drug was injected 15 minutes before a meal (part 1) and before a meal and acetaminophen (part 2). Parts 1 and 2 of study B enrolled six and eight patients, respectively. RESULTS: In both studies, plasma exenatide pharmacokinetic profiles appeared dose proportional. Exenatide doses of 0.02-0.2 microg/kg dose-dependently lowered postprandial glucose excursions. Exenatide suppressed postprandial plasma glucagon and slowed gastric emptying. There were no serious adverse events and no patient withdrawals related to treatment. Nausea and vomiting were the most common adverse events and were mild to moderate in severity at doses ranging from 0.02 to 0.2 microg/kg. CONCLUSION: Administration of preprandial exenatide by s.c. injection resulted in dose-proportional exenatide pharmacokinetics and antidiabetic pharmacodynamic activity. At doses ranging from 0.02 to 0.2 microg/kg, exenatide dose-dependently reduced postprandial plasma glucose excursion by insulinotropism, suppression of plasma glucagon, and slowing of gastric emptying.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Research works printed but not linked: 6
- 2002, J Clin Endocrinol Metab, 87, 1282, 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 2000, Endocrinology, 141, 1936, 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
- 2003, Curr Opin Investig Drugs, 4, 401
- 1999, J Clin Endocrinol Metab, 84, 1165, 10.1210/jcem.84.4.5612 · doi:10.1210/jcem.84.4.5612 · Paper page
- 1996, Diabet Med, 13, S34, 10.1002/dme.1996.13.s1.34 · doi:10.1002/dme.1996.13.s1.34
- 1987, Surg Gynecol Obstet, 165, 41
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“In human studies, the mean half-life ranged from 3.3 to 4 h (Kolterman et al., 2005).”
BackgroundInfluentialArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“Incretin mimetics provide a pharmacological stimulus to insulin secretion and elicit other GLP1-receptor-mediated activity as drugs, but are typically introduced at much higher concentrations compared with physiological levels of GLP-1 [65, 66].”
BackgroundBlevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Zinman, B., Hoogwerf, B. J., Durán García, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 427
Self-citationPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
Self-citationAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Self-citationTargeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
“The doses regarding exendin‐4 were selected based on previous data in other animal experiments and clinical trials.((17,18))”
MethodKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“Glucagon is a key regulator of normal fuel metabolism, and both fasting and postprandial hyperglucagonemia make substantial contributions to the fasting hyperglycemia and postprandial glucose excursions that characterize T2D.”
BackgroundResultInfluentialAbd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
“5 hours, which makes it feasible for twice-daily injections to provide sufficient plasma concentrations over a period of at least 4–6 hours.([28,39,40]) Exenatide reduced HbA1c by 0.”
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004274432 · Cited by 82
Self-citationBarnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63
“3–4 hours [6], exenatide has to be injected subcutaneous twice a day.”
BackgroundEffect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61
Pinelli, N. R., & Hurren, K. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q024 · Cited by 59
Exenatide-Induced Acute Pancreatitis
Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09104.crr · Cited by 58
Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men
Soon, D., Kothare, P. A., Linnebjerg, H., Park, S., Yuen, E., Mace, K. F., & Wise, S. D. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291622 · Cited by 54
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine
McCall, A. L., Cox, D. J., Brodows, R., Crean, J., Johns, D., & Kovatchev, B. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0107 · Cited by 46
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Kothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-8 · Cited by 35
Violante, R., Oliveira, J. H. A., Yoon, K. ‐., Reed, V. A., Yu, M. B., Bachmann, O. P., Lüdemann, J., & Chan, J. Y. C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03624.x · Cited by 35
Bergenstal, R. M., Li, Y., Porter, T. K. B., Weaver, C., & Han, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12026 · Cited by 31
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Potential use of exenatide for the treatment of obesity
Folli, F., & Guardado Mendoza, R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.630660 · Cited by 26
Metadata
- Authors
- Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-15
- Volume
- 62
- Issue
- 2
- Pages
- 173-181
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2344620176
- Cited by
- 434
- References
- 32
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.